Sign in

    Quentin Blackford

    President, Chief Executive Officer, Director at iRhythm Technologies Inc
    Board
    Since October 2021
    Age
    45 years
    Education
    Holds dual B.S. degrees in Accounting and Business Administration from Grace College.
    Tenure
    Joined iRhythm Technologies, Inc. in October 2021 as President, Chief Executive Officer, and Director.

    Also at iRhythm Technologies Inc

    CP
    Chad Patterson
    Chief Commercial Officer
    DW
    Daniel Wilson
    Chief Financial Officer
    MS
    Mervin Smith
    EVP of Business Operations

    About

    Quentin S. Blackford is a seasoned executive with extensive experience in the medical devices and healthcare technology industries, having held key leadership roles that have shaped industry practices over the past two decades. His career includes significant tenures as Chief Operating Officer at Dexcom and Chief Financial Officer at NuVasive, where he was instrumental in driving operational excellence and financial discipline.

    In his earlier career, he developed a strong foundation in financial and operational management while serving at Zimmer Holdings, culminating in a role as Director of Finance and Controller of the Dental Division. These positions allowed him to sharpen his skills in strategic oversight and business transformation, preparing him for executive leadership roles later in his career.

    Beyond his professional achievements, Blackford has also contributed his expertise as an independent board member for companies such as Alphatec Holdings and Paragon 28, further demonstrating his commitment to advancing innovative solutions in the healthcare sector. His background as a Certified Public Accountant (inactive) and his solid educational foundation have complemented his leadership, enabling him to make impactful decisions that drive company growth and operational improvements.

    $IRTC Performance Under Quentin Blackford

    Past Roles

    OrganizationRoleDate RangeDetails
    Dexcom, Inc. Chief Operating Officer September 2017 - September 2021 N/A
    Dexcom, Inc. Chief Financial Officer September 2017 - September 2021 N/A
    NuVasive, Inc. Executive Vice President, Chief Financial Officer, and Head of Strategy and Corporate Integrity February 2009 - September 2017 N/A
    Zimmer Holdings, Inc. Director of Finance and Controller of the Dental Division, Leader of the Global Financial Planning and Analysis group June 1999 - September 2009 N/A

    External Roles

    OrganizationRoleDate Range
    Paragon 28, Inc. Independent Board Member Since August 2022
    Alphatec Holdings, Inc. Independent Board Member Since October 2017

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Salary$677,463AnnualFixed base salary for 2023
    All Other Compensation$29,065AnnualIncludes severance & related benefits (if applicable), company-paid health plan, group term life insurance, wellness plan, and 401(k) matching up to $5,000 per year

    Performance Compensation

    Data from  FY 2023

    Annual Bonus Plan

    MetricValueDetailsCitation
    Target Bonus$675,000-
    Final Bonus$716,000 (106% of target)Based on actual performance metrics
    Revenue Weight75%Threshold: 50%, Target: 100%, Max: 200%
    Adjusted EBITDA Weight25%Threshold: 50%, Target: 100%, Max: 200%
    Revenue Achieved$492.7 millionAchieved 111% payout; weighted contribution 83%
    Adjusted EBITDA Achieved$(4.9) millionAchieved 70% payout; weighted contribution 18%
    Individual Performance Factor105%Reflects personal leadership and achievement of strategic goals

    Equity Awards - Annual RSUs & PSUs

    ComponentTarget Units/AmountVesting ScheduleDetailsCitation
    Annual RSUs28,775 unitsVest over 4 years; 25% vest on first anniversary (March 1, 2023) then annuallyGrant Date Fair Value: $3,460,194
    Annual PSUs28,775 unitsVest over the performance period (2023-2025), certified by March 15, 2026Grant Date Fair Value: $4,022,457; subject to performance metrics including Unit Volume CAGR and Relative TSR modifiers

    Equity Awards - Strategic PSUs

    MetricTargetMaximumVesting ScheduleDetailsCitation
    Target Units48,534 units72,801 units (150% of target)3-year cliff; vesting contingent on meeting operational goals and R-TSR performance; vesting date on August 7, 2026Grant Date Fair Value: $7,689,970; conditions include achieving 2 of 3 operational goals and R-TSR modifier (negative 25% if below 33rd percentile, positive 25% if above 75th percentile, capped at 150%)
    Target Value$5,000,000$7,500,000-Units calculated based on a 20 trading-day average closing price on the grant date